This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.5 | Special Copayment Reduction: V117 (5 years) |
| B. Synonyms | Primary familial xanthomatosis, infantile LAL deficiency, acid lipase deficiency (severe infantile form), cholesteryl ester storage disease (severe form) |
| C. Adult onset | Possibility of first presenting in adulthood very low — severe infantile-onset disease with onset within weeks of birth; death within 12 months of life without treatment |
| 1. History | 1956 first case description by Wolman, enzyme deficiency identified in the 1960s-70s, 2015 FDA approval of sebelipase alfa |
| 2. Causes | LIPA gene mutation causes complete lysosomal acid lipase deficiency → accumulation of cholesteryl esters and triglycerides within lysosomes |
| 3. Genetics | Autosomal recessive inheritance; LIPA gene (10q23.31); about 100 pathogenic variants identified; homozygous or compound heterozygous |
| 4. Epidemiology | Estimated 1 per 350,000-500,000 births; extremely rare disease; no sex or ethnic bias |
| 5. Pathophysiology | Complete LAL deficiency → massive accumulation of CE and TG within lysosomes → damage to liver, adrenal, and intestinal tissue → multiple organ failure |
| 6. Symptoms | Vomiting, diarrhea, growth failure, abdominal distension, hepatosplenomegaly; rapid generalized weakness and multiple organ failure within 1-2 months of life |
| 7. Signs | Bilateral adrenal calcification (abdominal CT), hepatosplenomegaly, jaundice, ascites; pancytopenia and abnormal liver function on blood tests |
| 8. Screening | Measurement of LAL enzyme activity in infant DBS; newborn screening program at the research stage; molecular screening when there is a family history |
| 9. Diagnosis | Measurement of leukocyte/DBS LAL enzyme activity, LIPA gene analysis, tissue biopsy, confirmation of adrenal calcification on abdominal CT |
| 10. Treatment | Sebelipase alfa (Kanuma®) enzyme replacement therapy FDA-approved (2015); intravenous administration twice weekly or once every two weeks |
| 11. Prognosis | Without treatment, most die within 6-12 months of life; survival can be markedly improved by early ERT |
| 12. Prevention | Genetic counseling, carrier testing, prenatal diagnosis (CVS/amniocentesis), preimplantation genetic testing (PGT-M) |
| 13. References | Bernstein DL et al. (2013) J Inherit Metab Dis and 9 other papers |
The first clinical description of Wolman disease was made in 1956 by the Iranian physician Moshé Wolman. He published in an Israeli medical journal the case of two siblings who died within a few months of birth with hepatosplenomegaly, adrenal calcification, severe diarrhea, and growth failure in infancy, and the disease subsequently became known as "Wolman disease" or "primary familial xanthomatosis." In 1971, Patrick and Lake showed through enzyme studies that the disease is caused by deficiency of lysosomal acid lipase (LAL). Subsequently, histopathological studies in the 1970s-80s confirmed that cholesteryl esters and triglycerides accumulate massively within lysosomes in various organs including the liver, adrenal glands, and intestine.
With advances in molecular genetics, the LIPA gene encoding LAL was identified at 10q23.31, and several hundred pathogenic variants have since been reported. From the late 1990s, research toward developing enzyme replacement therapy (ERT) began in earnest, and in December 2015 the US FDA approved sebelipase alfa (Kanuma®), a recombinant human LAL, for the treatment of Wolman disease and cholesteryl ester storage disease (CESD). This marked the birth of the first disease-modifying treatment in the history of Wolman disease and fundamentally changed the prognosis of a disease in which, in the past, all patients died within the first year of life. In Korea it is registered under Special Copayment Reduction code V117 (ICD-10: E75.5).
Wolman disease is caused by complete deficiency of lysosomal acid lipase (LAL) due to pathogenic variants of the LIPA gene. LAL is the key enzyme that, after low-density lipoprotein (LDL) particles enter the cell by endocytosis, hydrolyzes the cholesteryl esters (CE) and triglycerides (TG) they contain into free cholesterol and fatty acids within lysosomes. The LIPA gene is located at 10q23.31 on the long arm of chromosome 10 and consists of 10 exons.
Wolman disease is defined as a state in which LAL enzyme activity is completely or almost completely lost (less than 1% of normal), and this is mostly caused by severe pathogenic variants of the LIPA gene (premature stop codon, frameshift, splice site variants, etc.). In contrast, when mutations in the same LIPA gene leave 1-12% residual enzyme activity, a milder phenotype, cholesteryl ester storage disease (CESD), results, which can present at various times from childhood to adulthood. CESD and Wolman disease are understood as the two extremes of the mutation spectrum of the same gene. In particular, c.894G>A (p.Glu298=, exon 8 splice site variant), which is common in CESD, is generally not observed in Wolman disease patients.
Wolman disease follows an autosomal recessive mode of inheritance. Both parents must be carriers of pathogenic variants of the LIPA gene, and in that case 25% of their children are affected. Carrier parents are usually asymptomatic. The LIPA gene is located at 10q23.31, consists of 10 exons spanning 27 kb, and encodes LAL (acid lipase A, lysosomal acid cholesterol ester hydrolase). The mature LAL protein is a glycoprotein of 372 amino acids.
More than 100 LIPA pathogenic variants have been reported to date, most of them private mutations specific to individual families. However, some founder mutations have also been identified. Mutations characteristically observed in Wolman disease include an exon 4 deletion (Δexon 4), c.260G>A (p.Gly87Glu), and c.631C>T (p.Arg211Ter). The frequency of founder mutations is relatively high in Southwest Asian populations (Iranian and Iraqi Jews, etc.). A homozygous or compound heterozygous state with complete loss of LAL activity causes Wolman disease, and if even slight residual activity remains, the phenotype shifts toward CESD.
In the genotype-phenotype correlation, having two severe null variants (nonsense, frameshift) always results in the Wolman disease phenotype, and a combination of one severe variant and one mild variant (e.g., c.894G>A) often shows the CESD phenotype.
Wolman disease is an extremely rare disease, and its exact incidence is difficult to estimate. Depending on the literature, an incidence of about 1 per 300,000-500,000 births is reported, and it is estimated that several dozen new cases are diagnosed worldwide each year. There is no difference in occurrence by sex, and it can occur in all ethnic groups, although relatively higher frequencies due to a founder effect are reported in some groups (Jews of the Middle East, Iranians, Pakistanis).
The prevalence of LAL deficiency as a whole, including CESD, is estimated more broadly at 1 per 40,000-300,000 births, and CESD is diagnosed much less often than Wolman disease because symptoms are mild or it is often misdiagnosed as chronic liver disease. The number of Wolman disease patients registered in rare disease registries in the United States and Europe is only in the dozens, and worldwide about several hundred patients have been reported. Case reports are very rare in Korea, and there are no precise domestic prevalence data.
When LDL particles taken into the cell by receptor-mediated endocytosis are degraded in the endosome/lysosome pathway, lysosomal acid lipase (LAL) hydrolyzes CE and TG into free cholesterol and free fatty acids. When LAL is completely deficient, this degradation process is interrupted and CE and TG accumulate massively within lysosomes.
Accumulation of CE and TG within lysosomes triggers the following chain of reactions. First, because intracellular free cholesterol decreases, the SREBP (sterol regulatory element-binding protein) pathway is activated, and LDL receptor expression and endogenous cholesterol synthesis increase. This leads to a vicious cycle in which more LDL enters the cell and increases the lysosomal burden. Second, because of overall impairment of lysosomal function, the autophagy pathway is damaged and intracellular protein degradation declines.
In the liver, CE and TG accumulate in both Kupffer cells and hepatocytes, progressing to hepatocyte fatty infiltration, inflammation, fibrosis, and ultimately cirrhosis. In the adrenal glands, CE accumulation in cortical cells causes adrenal hypofunction and adrenal calcification. In the small intestine, CE and TG accumulate in absorptive epithelial cells, causing malabsorption, protein-losing enteropathy, and severe diarrhea. This multiple organ damage acts in combination to cause the rapid deterioration and death seen in infancy.
Wolman disease is a severe infantile-onset disease with symptoms appearing within a few weeks of birth. Initial symptoms include vomiting, abdominal distension, severe diarrhea (steatorrhea), feeding difficulty, and growth failure, followed by rapid weight loss and generalized weakness.
Vomiting, abdominal distension, diarrhea (steatorrhea), and feeding refusal appear from 2-4 weeks of life. Protein-losing enteropathy due to malabsorption progresses, resulting in hypoalbuminemia and malnutrition. At this stage, hepatosplenomegaly is confirmed on abdominal ultrasound or CT.
Severe failure to thrive is characteristic, falling off the growth curve within 2-3 months of life. Muscle wasting and generalized cachexia progress rapidly.
Hepatomegaly appears due to CE and TG accumulation in hepatocytes, followed by progression to hepatic fibrosis and liver failure. Liver function abnormalities such as elevated AST, ALT, and alkaline phosphatase, hypoalbuminemia, and prolonged prothrombin time are observed.
Adrenal insufficiency due to CE accumulation in the adrenal cortex can occur, causing hypoglycemia, electrolyte abnormalities, and so on. Bilateral adrenal calcification observed on abdominal CT is a pathological hallmark of Wolman disease.
In advanced cases, pancytopenia and anemia may appear, reflecting bone marrow involvement or anemia of chronic disease.
Without treatment, most die of multiple organ failure within 6-12 months of life.
The clinical signs of Wolman disease are observed on various examinations.
Bilateral adrenal calcification is the most characteristic imaging finding of Wolman disease and can be confirmed on plain abdominal radiography or CT. It is an important clue for diagnosis, and when unexplained adrenal calcification is found in an infant, Wolman disease should be suspected immediately. Hepatosplenomegaly, ascites, and mesenteric lymphadenopathy are also observed on abdominal ultrasound and CT.
Elevated serum AST, ALT, GGT, and alkaline phosphatase, hypoalbuminemia, coagulation factor deficiency (prolonged PT), elevated serum triglycerides and LDL cholesterol, and decreased HDL cholesterol may be seen. Along with pancytopenia, vacuolation within leukocytes may also be observed in peripheral blood.
Liver biopsy shows microvesicular steatosis, lipid vacuoles in Kupffer cells and hepatocytes, and fibrosis. On Oil Red O staining, large numbers of positive lipid droplets are observed, and electron microscopy confirms deposition of CE crystals within lysosomes. Foamy histiocytes may also be found on bone marrow aspiration.
There is currently no standardized population-based newborn screening program for Wolman disease, but the following approaches are used in research or clinical practice.
LAL enzyme activity can be measured in infant dried blood spots (DBS) using a fluorescent substrate. This method was highly standardized by Lohse et al., and its applicability as newborn screening is being studied. If LAL activity is less than 10% of normal controls, LAL deficiency is suspected and confirmatory testing proceeds. However, there is as yet no country in which this method is included in the standard newborn screening panel.
LAL deficiency should be included in the differential diagnosis when unexplained infantile hepatosplenomegaly, growth failure, and persistent diarrhea are present together. If bilateral adrenal calcification is confirmed on abdominal CT, LAL enzyme activity and LIPA gene testing are performed immediately. Because it is often not detected by general newborn screening, clinical awareness is most important.
Through carrier screening of the patient's family (LIPA gene analysis), prenatal diagnosis or PGT can be planned for future pregnancies. In siblings, DBS LAL enzyme activity measurement and genetic analysis are performed early.
The diagnosis of Wolman disease is confirmed by combining LAL enzyme activity measurement, LIPA gene analysis, and histopathological findings.
LAL enzyme activity is measured in leukocytes, fibroblasts, or dried blood spots (DBS). An enzyme assay using a fluorescent substrate such as 4-methylumbelliferyl oleate is the standard. In Wolman disease patients, LAL activity is mostly less than 1% of normal controls. Before testing, blood samples must be processed and stored under appropriate conditions to prevent false negatives.
For molecular genetic confirmation, direct sequencing of the LIPA gene (Sanger sequencing) or an NGS panel test is performed. If pathogenic variants are identified in both alleles, the diagnosis can be confirmed. Genetic testing is also used for carrier identification within the family and prenatal diagnosis.
Confirming bilateral adrenal calcification on abdominal CT is particularly important in diagnosing Wolman disease. When unexplained adrenal calcification is found in an infant, it strongly suggests Wolman disease. The degree of hepatosplenomegaly and liver echo changes are assessed by abdominal ultrasound.
Liver biopsy confirms fatty infiltration, fibrosis, and foam cells, and Oil Red O staining visualizes lipid accumulation. Electron microscopy can confirm deposition of CE crystals within lysosomes. Enzyme activity measurement through skin fibroblast culture is also possible.
Enzyme replacement therapy (ERT) is the mainstay of treatment for Wolman disease, and the prognosis has fundamentally improved since FDA approval in 2015.
Sebelipase alfa, a recombinant human LAL, received FDA approval in December 2015 and EMA approval in 2016. For severe infantile (under 1 year) patients it is administered intravenously twice weekly (3 mg/kg), after which the dose is increased up to 5 mg/kg according to clinical response. For children 1 year and older and adults with LAL deficiency (CESD), the standard dose is 1 mg/kg once every two weeks. In clinical studies, sebelipase alfa treatment showed normalization of liver function markers (AST, ALT), reduction of hepatosplenomegaly, improvement of growth failure, improvement of dyslipidemia, and markedly improved survival. Long-term follow-up studies (up to 10 years) also confirmed sustained treatment effect and acceptable safety.
Supportive treatments such as nutritional support (high-calorie oral or intravenous nutrition), steroid replacement for adrenal hypofunction, transfusion for anemia, and fresh frozen plasma for coagulopathy are combined with ERT. Parenteral nutrition (TPN) may be needed in cases of severe digestive and absorptive disorder.
HSCT was attempted in some cases before the introduction of sebelipase alfa, but because treatment-related morbidity and mortality were high and results were inconsistent, it now remains only as an alternative treatment considered when ERT fails or is unavailable.
Before sebelipase alfa treatment was introduced, the prognosis of Wolman disease was extremely poor. Most untreated patients died by 6 months of life, and almost all within 12 months, of multiple organ failure and malnutrition. Survival through hematopoietic stem cell transplantation was reported in a few cases, but transplant-related mortality was high, making wide application difficult.
Since the introduction of sebelipase alfa ERT, the prognosis of Wolman disease has improved dramatically. In a clinical trial (VITAL study), 1-year survival of treated infant patients was about 58% (placebo group: 0%), and longer survival has since been reported in open-label extension studies and real-world clinical experience. Early diagnosis and early initiation of ERT are the key factors determining prognosis. In particular, the earlier treatment is started, before or at the beginning of symptom onset, the more complications such as hepatic fibrosis, malnutrition, and adrenal hypofunction can be minimized. In long-term sebelipase alfa studies, patients surviving more than 10 years are being reported, and there are cases in which their physical development and liver function have been maintained at normal or near-normal levels.
Wolman disease is an autosomal recessive genetic disease for which no primary prevention exists, but the birth of affected children can be prevented through a genetic approach.
Because both parents of a Wolman disease patient are LIPA gene carriers, genetic counseling must be provided. The recurrence risk in later pregnancies (25%), confirmation of carrier status, prenatal diagnosis methods, and so on are explained in detail.
Carrier testing for LIPA gene mutations is performed in the patient's family (siblings, uncles and aunts, etc.). In high-risk ethnic groups, carrier screening before marriage or before planning pregnancy is considered.
When pathogenic variants of both parents have been identified, prenatal diagnosis is possible in later pregnancies by LIPA gene analysis or LAL enzyme activity measurement of the fetus through chorionic villus sampling (CVS, 10-12 weeks of gestation) or amniocentesis (14-16 weeks of gestation).
Through preimplantation genetic testing (PGT-M) performed together with in vitro fertilization, embryos unaffected by Wolman disease can be selectively transferred, thereby preventing the birth of affected children.
It is not yet included in national standard newborn screening, but early detection is possible by measuring LAL enzyme activity using DBS. Immediate initiation of ERT before symptom onset or after early diagnosis offers the best prognosis.